New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2014
04:55 EDTCYH, CYH, BAX, BAX, CAH, CAH, KND, KND, CRY, CRY, MDCO, MDCO, SRDX, SRDX, XOMA, XOMA, PRGO, PRGO, IDRA, IDRA, EBS, EBS, CVS, CVSRBC Capital to hold a conference
Healthcare Conference is being held in New York on February 25-26.
News For CYH;EBS;IDRA;PRGO;XOMA;SRDX;MDCO;CRY;KND;CAH;BAX;CVS From The Last 14 Days
Check below for free stories on CYH;EBS;IDRA;PRGO;XOMA;SRDX;MDCO;CRY;KND;CAH;BAX;CVS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 15, 2014
09:59 EDTCVSOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:16 EDTBAXOn The Fly: Pre-market Movers
Subscribe for More Information
09:01 EDTBAXBaxter announces FDA approval for RIXUBIS
(BAX) announced that the U.S. Food and Drug Administration has approved RIXUBIS for routine prophylactic treatment, control and prevention of bleeding episodes, and perioperative management in children with hemophilia B. RIXUBIS was the first recombinant factor IX approved for routine prophylaxis and control of bleeding episodes in the U.S. for adults living with this chronic condition. The approval is based on the results of a clinical trial investigating the efficacy and safety of RIXUBIS among 23 previously-treated male patients less than 12 years of age with severe or moderately severe hemophilia B. There were no reports of inhibitor development, no severe allergic reactions, and no thrombotic or treatment-related adverse events among the study participants. Baxter’s application for marketing approval for RIXUBIS for adults and pediatric patients is currently under review in the EU, with a regulatory decision expected later this year. The treatment also recently gained regulatory approval in Australia.
07:24 EDTCVSCVS Health upgraded at Cowen
Subscribe for More Information
06:07 EDTCVSCVS Health upgraded to Outperform from Market Perform at Cowen
September 12, 2014
20:32 EDTBAXFDA approves Baxter's HYQVIA for treatment of primary immunodeficiency
Subscribe for More Information
12:12 EDTMDCOThe Medicines Co. to host conference call
Subscribe for More Information
10:00 EDTCYHOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:23 EDTCYHCommunity Health initiated with an Outperform at Leerink
Subscribe for More Information
September 11, 2014
08:15 EDTBAXBaxter says separation on track for mid-2015, new company to be called 'Baxalta'
Subscribe for More Information
07:32 EDTCAHCardinal Health appoints Michael C. Kaufmann as CFO
Cardinal Health has named Michael C. Kaufmann, 51, CFO effective Nov. 11. This follows the previously announced planned retirement of current CFO Jeffrey W. Henderson, 49. Jon Giacomin, 49, has been named to the role of CEO of the Pharmaceutical segment, currently held by Mike Kaufmann, also effective Nov. 11.
September 9, 2014
12:14 EDTCYHHospitals rise after analyst says positive trends continuing
Subscribe for More Information
07:37 EDTCYHDeutsche Bank ups price targets in Hospital space
Subscribe for More Information
September 8, 2014
13:53 EDTEBSEmergent BioSolutions awarded contract valued at up to $29M with NIAID
Emergent BioSolutions has signed a contract with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to develop a dry formulation of NuThrax, also known as AV7909, the company’s next generation anthrax vaccine candidate. This five-year contract, valued at up to $29M, provides funding for manufacturing and non-clinical activities through the preparation of an Investigational New Drug application to the U.S. Food and Drug Administration. The dry formulation of NuThrax is intended to increase stability of the vaccine candidate at ambient and higher temperatures, with the objective of eliminating the need for cold chain during shipping and storage. NuThrax is comprised of BioThrax in combination with the immunostimulatory oligodeoxynucleotide compound CPG 7909. The company is currently conducting a randomized, parallel-group, active-controlled, double-blind Phase 2 study designed to evaluate the safety and immunogenicity of NuThrax for post-exposure prophylaxis of anthrax infection using two- and three-dose immunization schedules and two dose levels. This development contract HHSN272201400038C will be administered through NIAID, part of the National Institutes of Health of the U.S. Department of Health and Human Services.
10:51 EDTEBSEmergent BioSolutions receives $29M HHS contract
Subscribe for More Information
08:01 EDTCVSCVS Health completes purchase of Navarro Discount Pharmacy
Subscribe for More Information
07:26 EDTCVSMorgan Stanley to hold a conference
Subscribe for More Information
05:47 EDTBAXBaxter price target raised to $96 from $85 at Piper Jaffray
Subscribe for More Information
September 5, 2014
10:07 EDTSRDXSurModics management to meet with Barrington
Subscribe for More Information
September 4, 2014
13:17 EDTCYHTennessee AG tells Community Health patients to check credit
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use